Search

Your search keyword '"Kuipers, E"' showing total 762 results
Start Over Author "Kuipers, E" Search Limiters Full Text
762 results on '"Kuipers, E"'

2. Longitudinal symptomatic interactions in long-standing schizophrenia: A novel five-point analysis based on directed acyclic graphs

Author

Moffa, G, Kuipers, J, Carra, G, Crocamo, C, Kuipers, E, Angermeyer, M, Brugha, T, Toumi, M, Bebbington, P, Moffa G., Kuipers J., Carra G., Crocamo C., Kuipers E., Angermeyer M., Brugha T., Toumi M., Bebbington P., Moffa, G, Kuipers, J, Carra, G, Crocamo, C, Kuipers, E, Angermeyer, M, Brugha, T, Toumi, M, Bebbington, P, Moffa G., Kuipers J., Carra G., Crocamo C., Kuipers E., Angermeyer M., Brugha T., Toumi M., and Bebbington P.

Abstract

Background Recent network models propose that mutual interaction between symptoms has an important bearing on the onset of schizophrenic disorder. In particular, cross-sectional studies suggest that affective symptoms may influence the emergence of psychotic symptoms. However, longitudinal analysis offers a more compelling test for causation: the European Schizophrenia Cohort (EuroSC) provides data suitable for this purpose. We predicted that the persistence of psychotic symptoms would be driven by the continuing presence of affective disturbance. Methods EuroSC included 1208 patients randomly sampled from outpatient services in France, Germany and the UK. Initial measures of psychotic and affective symptoms were repeated four times at 6-month intervals, thereby furnishing five time-points. To examine interactions between symptoms both within and between time-slices, we adopted a novel technique for modelling longitudinal data in psychiatry. This was a form of Bayesian network analysis that involved learning dynamic directed acyclic graphs (DAGs). Results Our DAG analysis suggests that the main drivers of symptoms in this long-term sample were delusions and paranoid thinking. These led to affective disturbance, not vice versa as we initially predicted. The enduring relationship between symptoms was unaffected by whether patients were receiving first- or second-generation antipsychotic medication. Conclusions In this cohort of people with chronic schizophrenia treated with medication, symptoms were essentially stable over long periods. However, affective symptoms appeared driven by the persistence of delusions and persecutory thinking, a finding not previously reported. Although our findings as ever remain hostage to unmeasured confounders, these enduring psychotic symptoms might nevertheless be appropriate candidates for directly targeted psychological interventions.

Published
2023

3. Exploring Patient’s Perspectives and Experiences After Start with Inhalation Maintenance Therapy: A Qualitative Theory-Based Study

Author

Kuipers E, Wensing M, De Smet PAGM, and Teichert M

Subjects
inhalation therapy, asthma, copd, pharmaceutical care, pharmacy practice research, consultation, patient perspective, Medicine (General), R5-920
Abstract

Esther Kuipers, 1, 2 Michel Wensing, 1, 3 Peter AGM De Smet, 1, 4 Martina Teichert 5 1Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of IQ Healthcare, Nijmegen 6500 HB, The Netherlands; 2BENU Apotheek Zeist West, Zeist, The Netherlands; 3University Hospital Heidelberg, Department of General Practice and Health Services Research, Heidelberg, Germany; 4Radboud University Medical Centre, Radboud Institute for Health Sciences, Department of Clinical Pharmacy, Nijmegen, The Netherlands; 5Leiden University Medical Centre, Department of Clinical Pharmacy and Toxicology, Leiden, The NetherlandsCorrespondence: Esther KuipersRadboud University Medical Centre, Radboud Institute for Health Sciences, Department of IQ Healthcare, PO Box 9101, Nijmegen 6500 HB, The NetherlandsTel +31 24 361 0591Fax +31 24 354 0166Email esther.kuipers@radboudumc.nlBackground: Treatment of obstructive lung disease with inhalation therapy needs changes in patient behavior. Shortly after the start with inhaled corticosteroids (ICS) maintenance therapy, patients might be in need of additional pharmaceutical care, tailored to their individual needs. This study aimed to provide insight into patient behavior, goals and perceptions regarding their medical treatment at start with ICS therapy, by telephone interviews with ICS starters. Besides, this study investigated pharmacists’ and patients’ experiences with these interviews and opinions on the utility of this type of consultation for daily practice.Methods: Semi-structured telephone interviews were conducted by pharmacists with adult patients 2– 3 weeks after starting ICS. The Theoretical Domain Framework (TDF) was used for data analysis and coding. Afterward, the patients and pharmacists were questioned about their experiences with the interview.Results: Five pharmacists conducted interviews with 23 ICS starters. Except the domains “environmental context and resources”, “optimism”, and “reinforcement”, the remaining 11 domains in the TDF were addressed in the interviews. The majority of patients defined personal goals, which mainly addressed disease or symptom control (clinical goals). Some patients showed a lack of knowledge regarding the clinical indication or therapy duration. Views on beneficial medication effects differed between patients. Some patients specifically mentioned concerns or anxiety about side effects. The interviewees described different perceptions on the necessity of a personalized routine for regular medication use. Patients and pharmacists both felt positive about an added value of these interviews for daily practice.Conclusion: Patient interviews shortly after start with ICS therapy revealed various perceptions and beliefs that might influence medication use and achievement of individual treatment goals. The patients appreciated the opportunity to ask questions and share their perspectives and needs with their pharmacist, and the pharmacists experienced that the interviews had added value.Keywords: inhalation therapy, asthma, COPD, pharmaceutical care, pharmacy practice research, consultation, patient perspective

Published
2020

4. Ontwikkelingen voedselveiligheidsbeleid : kamerbrief

Author

Kuipers, E. and Kuipers, E.

Abstract

Het niveau van de voedselveiligheid in Nederland is hoog. Ook het consumentenvertrouwen in de veiligheid van ons voedsel is groot en al vele jaren redelijk stabiel zoals blijkt uit de recente uitkomsten van de Consumentenmonitor 2023 die door de NVWA periodiek wordt uitgevoerd.

Published
2023

5. Intensiveringsplan preventie vogelgriep (kamerbrief)

Author

Adema, P., Kuipers, E., Adema, P., and Kuipers, E.

Abstract

Wet- en regelgeving, beleid - Minister Adema (LNV) en minister Kuipers (VWS) informeren de Tweede Kamer over de intensivering van de aanpak van vogelgriep. De ministers sturen het intensiveringsplan preventie vogelgriep met deze Kamerbrief mee.

Published
2023

6. The Detrimental Impact of the COVID-19 Pandemic on Major Trauma Outcomes in the Netherlands

Author

Driessen, Mitchell L. S., Sturms, Leontien M., Bloemers, Frank W., Duis, Henk Jan ten, Edwards, Michael J. R., den Hartog, Dennis, Kuipers, E. J., Leenhouts, Peter A., Poeze, Martijn, Schipper, Inger B., Spanjersberg, Richard W., Wendt, Klaus W., de Wit, Ralph J., van Zutphen, Stefan W. A. M., de Jongh, Mariska A. C., and Leenen, Luke P. H.

Subjects
Adult, Male, trauma care, Critical Care, SARS-CoV-2, major trauma patient, COVID-19, Middle Aged, resource utilization, Brain Injuries, Traumatic, impact, Humans, Wounds and Injuries, Female, Triage, Emergency Service, Hospital, Pandemics, Facilities and Services Utilization, Aged, Netherlands
Abstract

Objective: To evaluate the impact of the COVID-19 pandemic on the outcome of major trauma patients in the Netherlands. Summary Background Data: Major trauma patients highly rely on immediate access to specialized services, including ICUs, shortages caused by the impact of the COVID-19 pandemic may influence their outcome. Methods: A multi-center observational cohort study, based on the Dutch National Trauma Registry was performed. Characteristics, resource usage, and outcome of major trauma patients (injury severity score ≥16) treated at all trauma-receiving hospitals during the first COVID-19 peak (March 23 through May 10) were compared with those treated from the same period in 2018 and 2019 (reference period). Results: During the peak period, 520 major trauma patients were admitted, versus 570 on average in the pre-COVID-19 years. Significantly fewer patients were admitted to ICU facilities during the peak than during the reference period (49.6% vs 55.8%; P=0.016). Patients with less severe traumatic brain injuries in particular were less often admitted to the ICU during the peak (40.5% vs 52.5%; P=0.005). Moreover, this subgroup showed an increased mortality compared to the reference period (13.5% vs 7.7%; P=0.044). These results were confirmed using multivariable logistic regression analyses. In addition, a significant increase in observed versus predicted mortality was recorded for patients who had a priori predicted mortality of 50% to 75% (P=0.012). Conclusions: The COVID-19 peak had an adverse effect on trauma care as major trauma patients were less often admitted to ICU and specifically those with minor through moderate brain injury had higher mortality rates.

Published
2021

7. The RT-18: a new screening tool to assess young adult risk-taking behavior

Author

de Haan L, Kuipers E, Kuerten Y, van Laar M, Olivier B, and Verster JC

Subjects
Medicine (General), R5-920
Abstract

Lydia de Haan1, Esther Kuipers1, Yvanca Kuerten1, Margriet van Laar2, Berend Olivier1, Joris Cornelis Verster11Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University; 2Trimbos Institute, Netherlands Institute of Mental Health and Addiction, Utrecht, The NetherlandsAbstract: Risk-taking behavior is a major determinant of health and plays a central role in various diseases. Therefore, a brief questionnaire was developed to assess risk taking among young adults with known different levels of risk-taking behavior (social drinkers and recreational drug users). In Study 1, N = 522 university students completed the RT-18 risk taking questionnaire. N = 100 students were retested after 2 to 4 weeks and performed the Cambridge Gambling Task (CGT). Mean RT-18 score was 7.69 and Cronbach's alpha was 0.886. The test-retest reliability was r = 0.94. Significant correlation was found between the RT-18 score and CGT scores of risk taking, bet proportion, and risk adjustment. In Study 2, N = 7834 young adult social drinkers, and recreational drug users, mean RT-18 score was 9.34 and Cronbach's alpha was 0.80. Factor analysis showed that the RT-18 comprises two factors assessing level of risk-taking behavior and risk assessment. Men scored significantly higher than women on the RT-18. Recreational drug users had significantly higher scores when compared to social drinkers. In Study 3 of N = 1000 students, construct validity was confirmed by showing that the RT-18 outcome correlates significantly with scores on the Stimulating-Instrumental Risk Inventory. In conclusion, the RT-18 is a valid and reliable screening tool to differentiate levels of risk-taking behavior. This short scale is quick and practical to administer, imposing minimal demands on participants. The RT-18 is able to differentiate risk taking and risk assessment which can help target appropriate intervention strategies.Keywords: risk taking, impulsivity, sensation seeking, venturesomeness, novelty seeking

Published
2011

8. Autophagy mediates ER stress and inflammation in Helicobacter pylori-related gastric cancer

Author

Mommersteeg, M. C., Simovic, I., Yu, B., van Nieuwenburg, S. A.V., Bruno, I, M.J., Doukas, M., Kuipers, E. J., Spaander, M. C.W., Peppelenbosch, M. P., Castaño-Rodríguez, N., Fuhler, G. M., Mommersteeg, M. C., Simovic, I., Yu, B., van Nieuwenburg, S. A.V., Bruno, I, M.J., Doukas, M., Kuipers, E. J., Spaander, M. C.W., Peppelenbosch, M. P., Castaño-Rodríguez, N., and Fuhler, G. M.

Published
2022

9. The Detrimental Impact of the COVID-19 Pandemic on Major Trauma Outcomes in the Netherlands A Comprehensive Nationwide Study

Author

Driessen, M.L.S., Sturms, L.M., Bloemers, F.W., Duis, H.J. ten, Edwards, M.J.R., Hartog, Dennis den, Kuipers, E., Jongh, Mariska A. C. de, Leenen, Luke P. H., Driessen, M.L.S., Sturms, L.M., Bloemers, F.W., Duis, H.J. ten, Edwards, M.J.R., Hartog, Dennis den, Kuipers, E., Jongh, Mariska A. C. de, and Leenen, Luke P. H.

Abstract

Item does not contain fulltext

Published
2022

10. Surveillance zoönosen in melkvee 2021

Author

Cuperus, T., Opsteegh, M., van der Ark, K., Neppelenbroek, N., Wit, B., Wullings, B., Kool, J., Dierikx, C., van Duijkeren, E., van den Hoek, A., Hengeveld, P., Bos, M., Kuipers, E., Giessen, Cuperus, T., Opsteegh, M., van der Ark, K., Neppelenbroek, N., Wit, B., Wullings, B., Kool, J., Dierikx, C., van Duijkeren, E., van den Hoek, A., Hengeveld, P., Bos, M., Kuipers, E., and Giessen

Abstract

Dieren kunnen ziekteverwekkers bij zich dragen waar mensen ook ziek van kunnen worden. De ziekten die hierdoor worden veroorzaakt, noemen we zoönosen. In 2021 onderzochten het RIVM, de NVWA en WFSR (Wageningen Food Safety Research) hoe vaak een aantal van deze ziekteverwekkers voorkwamen bij melkvee op 185 Nederlandse melkveebedrijven. Ook hebben 107 melkveehouders, gezinsleden en medewerkers aan dit onderzoek meegedaan om te kijken of zij deze ziekteverwekkers ook bij zich dragen. Bij de onderzochte koeien en kalveren komen een aantal ziekteverwekkers vaak voor. Ze zitten in de darmen van de dieren en dus ook in de mest. Melk kan tijdens het melken in aanraking komen met mest en op die manier besmet raken. Mensen kunnen de kans op een besmetting verkleinen door geen rauwe melk of rauwe melkproducten, zoals kaas, te consumeren. Het vlees kan tijdens de slacht besmet raken. Het is daarom belangrijk om rundvlees goed gaar te eten. Het RIVM heeft gekeken of dezelfde ziekteverwekkers in de ontlasting of in de neus van deze mensen voorkwamen. De meeste van deze ziekteverwekkers veroorzaken bij mensen diarree, maar soms kunnen infecties ernstiger verlopen. Daarnaast is er naar ESBL-producerende bacteriën en MRSA gekeken, omdat belangrijke groepen antibiotica daar niet tegen werken. Van de onderzochte ziekteverwekkers kwam Campylobacter het meest voor bij het melkvee: op 91 procent van de bedrijven. Bij de veehouders en gezinsleden werd Campylobacter bij 1 persoon gevonden. Het hoge percentage bij de dieren is dus niet direct terug te zien bij de veehouders. Daarnaast kwamen de Listeria en STEC-bacteriën regelmatig voor bij melkvee; namelijk op 34 procent (Listeria) en 21 procent (STEC) van de bedrijven. Twee deelnemers van de veehouders en gezinsleden droegen Listeria bij zich en één deelnemer STEC. ESBL-producerende bacteriën zijn op 8 procent van de bedrijven gevonden en bij 3 deelnemers. Het percentage bij de deelnemers is ongeveer hetzelfde als bij de Nederlands

Published
2022

11. Population-Based Prevalence of Gastrointestinal Abnormalities at Colon Capsule Endoscopy

Author

Vuik, F. E. R., Nieuwenburg, S. A. V., Moen, S., Schreuders, E. H., Oudkerk Pool, M. D., Peterse, E. F. P., Spada, Cristiano, Epstein, O., Fernández-Urién, I., Hofman, A., Kuipers, E. J., Spaander, M. C. W., Spada C. (ORCID:0000-0002-5692-0960), Vuik, F. E. R., Nieuwenburg, S. A. V., Moen, S., Schreuders, E. H., Oudkerk Pool, M. D., Peterse, E. F. P., Spada, Cristiano, Epstein, O., Fernández-Urién, I., Hofman, A., Kuipers, E. J., Spaander, M. C. W., and Spada C. (ORCID:0000-0002-5692-0960)

Abstract

BACKGROUND & AIMS: The population prevalence of gastrointestinal (GI) disease is unclear and difficult to assess in an asymptomatic population. The aim of this study was to determine prevalence of GI lesions in a largely asymptomatic population undergoing colon capsule endoscopy (CCE).METHODS: Participants aged between 50-75 years were retrieved from the Rotterdam Study, a longitudinal epidemiological study, between 2017-2019. Participants received CCE with bowel preparation. Abnormalities defined as clinically relevant were Barrett segment >3cm, severe ulceration, polyp >10 mm or >= 3 polyps in small bowel (SB) or colon, and cancer.RESULTS: Of 2800 invited subjects, 462 (16.5%) participants (mean age 66.8 years, female 53.5%) ingested the colon capsule. A total of 451 videos were analyzed, and in 94.7% the capsule reached the descending colon. At least 1 abnormal finding was seen in 448 (99.3%) participants. The prevalence of abnormalities per GI segment, and the most common type of abnormality, were as follows: Esophageal 14.8% (Barrett's esophagus <3 cm in 8.3%), gastric 27.9% (fundic gland polyps in 18.1%), SB abnormalities 33.9% (erosions in 23.8%), colon 93.3% (diverticula in 81.2%). A total of 54 participants (12%) had clinically relevant abnormalities, 3 (0.7%) in esophagus/stomach (reflux esophagitis grade D, Mallory Weiss lesion and severe gastritis), 5 (1.1%) in SB (polyps > 10 mm; n = 4, severe ulcer n = 1,) and 46 (10.2%) in colon (polyp > 10 mm or >= 3 polyps n = 46, colorectal cancer n = 1).CONCLUSIONS: GI lesions are very common in a mostly asymptomatic Western population, and clinically relevant lesions were found in 12% at CCE. These findings provide a frame of reference for the prevalence rates of GI lesions in the general population.

Published
2022

13. Accuracy of H. pylori fecal antigen test using fecal immunochemical test (FIT)

Author

Nieuwenburg, S. A.V., Mommersteeg, M. C., Wolters, L. M.M., van Vuuren, A. J., Erler, N., Peppelenbosch, M. P., Fuhler, G. M., Bruno, M. J., Kuipers, E. J., Spaander, M. C.W., Nieuwenburg, S. A.V., Mommersteeg, M. C., Wolters, L. M.M., van Vuuren, A. J., Erler, N., Peppelenbosch, M. P., Fuhler, G. M., Bruno, M. J., Kuipers, E. J., and Spaander, M. C.W.

Abstract

Background: Gastric and colorectal cancer (CRC) are both one of the most common cancers worldwide. In many countries fecal immunochemical tests (FIT)-based CRC screening has been implemented. We investigated if FIT can also be applied for detection of H. pylori, the main risk factor for gastric cancer. Methods: This prospective study included participants over 18 years of age referred for urea breath test (UBT). Patients were excluded if they had used antibiotics/bismuth in the past 4 weeks, or a proton pomp inhibitor (PPI) in the past 2 weeks. Participants underwent UBT, ELISA stool antigen test in standard feces tube (SAT), ELISA stool antigen test in FIT tube (Hp-FIT), and blood sampling, and completed a questionnaire on user friendliness. UBT results were used as reference. Results: A total of 182 patients were included (37.4% male, median age 52.4 years (IQR 22.4)). Of these, 60 (33.0%) tested H. pylori positive. SAT and Hp-FIT showed comparable overall accuracy 71.1% (95%CI 63.2–78.3) vs. 77.6% (95%CI 70.4–83.8), respectively (p = 0.97). Sensitivity of SAT was 91.8% (95%CI 80.4–97.7) versus 94.2% (95%CI 84.1–98.9) of Hp-FIT (p = 0.98). Serology scored low with an overall accuracy of 49.7% (95%CI 41.7–57.7). Hp-FIT showed the highest overall user convenience. Conclusions: FIT can be used with high accuracy and sensitivity for diagnosis of H. pylori and is rated as the most convenient test. Non-invasive Hp-FIT test is highly promising for combined upper and lower gastrointestinal (pre-) cancerous screening. Further research should investigate the clinical implications, benefits and cost-effectiveness of such an approach.

Published
2022

14. The Detrimental Impact of the COVID-19 Pandemic on Major Trauma Outcomes in the Netherlands:A Comprehensive Nationwide Study

Author

Driessen, Mitchell L.S., Sturms, Leontien M., Bloemers, Frank W., Duis, Henk Jan Ten, Edwards, Michael J.R., Den Hartog, Dennis, Kuipers, E. J., Leenhouts, Peter A., Poeze, Martijn, Schipper, Inger B., Spanjersberg, Richard W., Wendt, Klaus W., De Wit, Ralph J., Van Zutphen, Stefan W.A.M., De Jongh, Mariska A.C., Leenen, Luke P.H., Driessen, Mitchell L.S., Sturms, Leontien M., Bloemers, Frank W., Duis, Henk Jan Ten, Edwards, Michael J.R., Den Hartog, Dennis, Kuipers, E. J., Leenhouts, Peter A., Poeze, Martijn, Schipper, Inger B., Spanjersberg, Richard W., Wendt, Klaus W., De Wit, Ralph J., Van Zutphen, Stefan W.A.M., De Jongh, Mariska A.C., and Leenen, Luke P.H.

Abstract

Objective:To evaluate the impact of the COVID-19 pandemic on the outcome of major trauma patients in the Netherlands. Summary Background Data:Major trauma patients highly rely on immediate access to specialized services, including ICUs, shortages caused by the impact of the COVID-19 pandemic may influence their outcome. Methods:A multi-center observational cohort study, based on the Dutch National Trauma Registry was performed. Characteristics, resource usage, and outcome of major trauma patients (injury severity score ≥16) treated at all trauma-receiving hospitals during the first COVID-19 peak (March 23 through May 10) were compared with those treated from the same period in 2018 and 2019 (reference period).Results:During the peak period, 520 major trauma patients were admitted, versus 570 on average in the pre-COVID-19 years. Significantly fewer patients were admitted to ICU facilities during the peak than during the reference period (49.6% vs 55.8%; P=0.016). Patients with less severe traumatic brain injuries in particular were less often admitted to the ICU during the peak (40.5% vs 52.5%; P=0.005). Moreover, this subgroup showed an increased mortality compared to the reference period (13.5% vs 7.7%; P=0.044). These results were confirmed using multivariable logistic regression analyses. In addition, a significant increase in observed versus predicted mortality was recorded for patients who had a priori predicted mortality of 50% to 75% (P=0.012). Conclusions:The COVID-19 peak had an adverse effect on trauma care as major trauma patients were less often admitted to ICU and specifically those with minor through moderate brain injury had higher mortality rates.

Published
2022

15. The Detrimental Impact of the COVID-19 Pandemic on Major Trauma Outcomes in the Netherlands: A Comprehensive Nationwide Study

Author

Zorgeenheid Traumatologie, Infection & Immunity, Driessen, Mitchell L S, Sturms, Leontien M, Bloemers, Frank W, Duis, Henk Jan Ten, Edwards, Michael J R, den Hartog, Dennis, Kuipers, E J, Leenhouts, Peter A, Poeze, Martijn, Schipper, Inger B, Spanjersberg, Richard W, Wendt, Klaus W, de Wit, Ralph J, van Zutphen, Stefan W A M, de Jongh, Mariska A C, Leenen, Luke P H, Zorgeenheid Traumatologie, Infection & Immunity, Driessen, Mitchell L S, Sturms, Leontien M, Bloemers, Frank W, Duis, Henk Jan Ten, Edwards, Michael J R, den Hartog, Dennis, Kuipers, E J, Leenhouts, Peter A, Poeze, Martijn, Schipper, Inger B, Spanjersberg, Richard W, Wendt, Klaus W, de Wit, Ralph J, van Zutphen, Stefan W A M, de Jongh, Mariska A C, and Leenen, Luke P H

Published
2022

24. The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Author

Safiri, S, Sepanlou, S, Ikuta, K, Bisignano, C, Salimzadeh, H, Delavari, A, Ansari, R, Roshandel, G, Merat, S, Fitzmaurice, C, Force, L, Nixon, M, Abbastabar, H, Abegaz, K, Afarideh, M, Ahmadi, A, Ahmed, M, Akinyemiju, T, Alahdab, F, Ali, R, Alikhani, M, Alipour, V, Aljunid, S, Almadi, M, Almasi-Hashiani, A, Al-Raddadi, R, Alvis-Guzman, N, Amini, S, Anber, N, Ansari-Moghaddam, A, Arabloo, J, Arefi, Z, Asghari Jafarabadi, M, Azadmehr, A, Badawi, A, Baheiraei, N, Barnighausen, T, Basaleem, H, Behzadifar, M, Belayneh, Y, Berhe, K, Bhattacharyya, K, Biadgo, B, Bijani, A, Biondi, A, Bjorge, T, Borzi, A, Bosetti, C, Bou-Orm, I, Brenner, H, Briko, A, Briko, N, Carreras, G, Carvalho, F, Castaneda-Orjuela, C, Cerin, E, Chiang, P, Chido-Amajuoyi, O, Daryani, A, Davitoiu, D, Demoz, G, Desai, R, Dianati Nasab, M, Eftekhari, A, El Sayed, I, Elbarazi, I, Emamian, M, Endries, A, Esmaeilzadeh, F, Esteghamati, A, Etemadi, A, Farzadfar, F, Fernandes, E, Fernandes, J, Filip, I, Fischer, F, Foroutan, M, Gad, M, Gallus, S, Ghaseni-Kebria, F, Ghashghaee, A, Gorini, G, Hafezi-Nejad, N, Haj-Mirzaian, A, Hasanpour-Heidari, S, Hasanzadeh, A, Hassanipour, S, Hay, S, Hoang, C, Hostiuc, M, Househ, M, Ilesanmi, O, Ilic, M, Innos, K, Irvani, S, Islami, F, Jaca, A, Jafari Balalami, N, Jafari Delouei, N, Jafarinia, M, Jahani, M, Jakovljevic, M, James, S, Javanbakht, M, Jenabi, E, Jha, R, Joukar, F, Kasaeian, A, Kassa, T, Kassaw, M, Kengne, A, Khader, Y, Khaksarian, M, Khalilov, R, Khan, E, Khayamzadeh, M, Khazaee-Pool, M, Khazaei, S, Khosravi Shadmani, F, Khubchandani, J, Kim, D, Kisa, A, Kisa, S, Kocarnik, J, Komaki, H, Kopec, J, Koyanagi, A, Kuipers, E, Kumar, V, La Vecchia, C, Lami, F, Lopez, A, Lopukhov, P, Lunevicius, R, Majeed, A, Majidinia, M, Manafi, A, Manafi, N, Manda, A, Mansour-Ghanaei, F, Mantovani, L, Mehta, D, Meier, T, Meles, H, Mendoza, W, Mestrovic, T, Miazgowski, B, Miazgowski, T, Mir, S, Mirzaei, H, Mohammad, K, Mohammad Gholi Mezerji, N, Mohammadian-Hafshejani, A, Mohammadoo-Khorasani, M, Mohammed, S, Mohebi, F, Mokdad, A, Monasta, L, Moossavi, M, Moradi, G, Moradpour, F, Moradzadeh, R, Nahvijou, A, Naik, G, Najafi, F, Nazari, J, Negoi, I, Negru, S, Nguyen, C, Nguyen, T, Ningrum, D, Ogbo, F, Olagunju, A, Olagunju, T, Pana, A, Pereira, D, Pirestani, M, Pourshams, A, Poustchi, H, Qorbani, M, Rabiee, M, Rabiee, N, Radfar, A, Rahmati, M, Rajati, F, Raoofi, S, Rawaf, D, Rawaf, S, Reiner, R, Renzaho, A, Rezaei, N, Rezapour, A, Saad, A, Saadatagah, S, Saddik, B, Salehi, F, Zahabi, S, Salz, I, Samy, A, Sanabria, J, Santric Milicevic, M, Sarveazad, A, Satpathy, M, Schneider, I, Sekerija, M, Shaahmadi, F, Shabaninejad, H, Shamsizadeh, M, Sharafi, Z, Sharif, M, Sharifi, A, Sheikhbahaei, S, Shirkoohi, R, Siddappa Malleshappa, S, Silva, D, Sisay, M, Smarandache, C, Soofi, M, Soreide, K, Soshnikov, S, Starodubov, V, Tabares-Seisdedos, R, Sullman, M, Taherkhani, A, Tesfay, B, Topor-Madry, R, Traini, E, Tran, B, Tran, K, Ullah, I, Uthman, O, Vacante, M, Vahedian-Azimi, A, Valli, A, Varavikova, E, Vujcic, I, Westerman, R, Yazdi-Feyzabadi, V, Yisma, E, Yu, C, Zadnik, V, Zahirian Moghadam, T, Zaki, L, Zandian, H, Zhang, Z, Murray, C, Naghavi, M, Malekzadeh, R, Safiri S., Sepanlou S. G., Ikuta K. S., Bisignano C., Salimzadeh H., Delavari A., Ansari R., Roshandel G., Merat S., Fitzmaurice C., Force L. M., Nixon M. R., Abbastabar H., Abegaz K. H., Afarideh M., Ahmadi A., Ahmed M. B., Akinyemiju T., Alahdab F., Ali R., Alikhani M., Alipour V., Aljunid S. M., Almadi M. A. H., Almasi-Hashiani A., Al-Raddadi R. M., Alvis-Guzman N., Amini S., Anber N. H., Ansari-Moghaddam A., Arabloo J., Arefi Z., Asghari Jafarabadi M., Azadmehr A., Badawi A., Baheiraei N., Barnighausen T. W., Basaleem H., Behzadifar M., Belayneh Y. M., Berhe K., Bhattacharyya K., Biadgo B., Bijani A., Biondi A., Bjorge T., Borzi A. M., Bosetti C., Bou-Orm I. R., Brenner H., Briko A. N., Briko N. I., Carreras G., Carvalho F., Castaneda-Orjuela C. A., Cerin E., Chiang P. P. -C., Chido-Amajuoyi O. G., Daryani A., Davitoiu D. V., Demoz G. T., Desai R., Dianati Nasab M., Eftekhari A., El Sayed I., Elbarazi I., Emamian M. H., Endries A. Y., Esmaeilzadeh F., Esteghamati A., Etemadi A., Farzadfar F., Fernandes E., Fernandes J. C., Filip I., Fischer F., Foroutan M., Gad M. M., Gallus S., Ghaseni-Kebria F., Ghashghaee A., Gorini G., Hafezi-Nejad N., Haj-Mirzaian A., Hasanpour-Heidari S., Hasanzadeh A., Hassanipour S., Hay S. I., Hoang C. L., Hostiuc M., Househ M., Ilesanmi O. S., Ilic M. D., Innos K., Irvani S. S. N., Islami F., Jaca A., Jafari Balalami N., Jafari Delouei N., Jafarinia M., Jahani M. A., Jakovljevic M., James S. L., Javanbakht M., Jenabi E., Jha R. P., Joukar F., Kasaeian A., Kassa T. D., Kassaw M. W., Kengne A. P., Khader Y. S., Khaksarian M., Khalilov R., Khan E. A., Khayamzadeh M., Khazaee-Pool M., Khazaei S., Khosravi Shadmani F., Khubchandani J., Kim D., Kisa A., Kisa S., Kocarnik J. M., Komaki H., Kopec J. A., Koyanagi A., Kuipers E. J., Kumar V., La Vecchia C., Lami F. H., Lopez A. D., Lopukhov P. D., Lunevicius R., Majeed A., Majidinia M., Manafi A., Manafi N., Manda A. -L., Mansour-Ghanaei F., Mantovani L. G., Mehta D., Meier T., Meles H. G., Mendoza W., Mestrovic T., Miazgowski B., Miazgowski T., Mir S. M., Mirzaei H., Mohammad K. A., Mohammad Gholi Mezerji N., Mohammadian-Hafshejani A., Mohammadoo-Khorasani M., Mohammed S., Mohebi F., Mokdad A. H., Monasta L., Moossavi M., Moradi G., Moradpour F., Moradzadeh R., Nahvijou A., Naik G., Najafi F., Nazari J., Negoi I., Negru S., Nguyen C. T., Nguyen T. H., Ningrum D. N. A., Ogbo F. A., Olagunju A. T., Olagunju T. O., Pana A., Pereira D. M., Pirestani M., Pourshams A., Poustchi H., Qorbani M., Rabiee M., Rabiee N., Radfar A., Rahmati M., Rajati F., Raoofi S., Rawaf D. L., Rawaf S., Reiner R. C., Renzaho A. M. N., Rezaei N., Rezapour A., Saad A. M., Saadatagah S., Saddik B., Salehi F., Zahabi S. S., Salz I., Samy A. M., Sanabria J., Santric Milicevic M. M., Sarveazad A., Satpathy M., Schneider I. J. C., Sekerija M., Shaahmadi F., Shabaninejad H., Shamsizadeh M., Sharafi Z., Sharif M., Sharifi A., Sheikhbahaei S., Shirkoohi R., Siddappa Malleshappa S. K., Silva D. A. S., Sisay M., Smarandache C. -G., Soofi M., Soreide K., Soshnikov S., Starodubov V. I., Tabares-Seisdedos R., Sullman M., Taherkhani A., Tesfay B. E., Topor-Madry R., Traini E., Tran B. X., Tran K. B., Ullah I., Uthman O. A., Vacante M., Vahedian-Azimi A., Valli A., Varavikova E., Vujcic I. S., Westerman R., Yazdi-Feyzabadi V., Yisma E., Yu C., Zadnik V., Zahirian Moghadam T., Zaki L., Zandian H., Zhang Z. -J., Murray C. J. L., Naghavi M., Malekzadeh R., Safiri, S, Sepanlou, S, Ikuta, K, Bisignano, C, Salimzadeh, H, Delavari, A, Ansari, R, Roshandel, G, Merat, S, Fitzmaurice, C, Force, L, Nixon, M, Abbastabar, H, Abegaz, K, Afarideh, M, Ahmadi, A, Ahmed, M, Akinyemiju, T, Alahdab, F, Ali, R, Alikhani, M, Alipour, V, Aljunid, S, Almadi, M, Almasi-Hashiani, A, Al-Raddadi, R, Alvis-Guzman, N, Amini, S, Anber, N, Ansari-Moghaddam, A, Arabloo, J, Arefi, Z, Asghari Jafarabadi, M, Azadmehr, A, Badawi, A, Baheiraei, N, Barnighausen, T, Basaleem, H, Behzadifar, M, Belayneh, Y, Berhe, K, Bhattacharyya, K, Biadgo, B, Bijani, A, Biondi, A, Bjorge, T, Borzi, A, Bosetti, C, Bou-Orm, I, Brenner, H, Briko, A, Briko, N, Carreras, G, Carvalho, F, Castaneda-Orjuela, C, Cerin, E, Chiang, P, Chido-Amajuoyi, O, Daryani, A, Davitoiu, D, Demoz, G, Desai, R, Dianati Nasab, M, Eftekhari, A, El Sayed, I, Elbarazi, I, Emamian, M, Endries, A, Esmaeilzadeh, F, Esteghamati, A, Etemadi, A, Farzadfar, F, Fernandes, E, Fernandes, J, Filip, I, Fischer, F, Foroutan, M, Gad, M, Gallus, S, Ghaseni-Kebria, F, Ghashghaee, A, Gorini, G, Hafezi-Nejad, N, Haj-Mirzaian, A, Hasanpour-Heidari, S, Hasanzadeh, A, Hassanipour, S, Hay, S, Hoang, C, Hostiuc, M, Househ, M, Ilesanmi, O, Ilic, M, Innos, K, Irvani, S, Islami, F, Jaca, A, Jafari Balalami, N, Jafari Delouei, N, Jafarinia, M, Jahani, M, Jakovljevic, M, James, S, Javanbakht, M, Jenabi, E, Jha, R, Joukar, F, Kasaeian, A, Kassa, T, Kassaw, M, Kengne, A, Khader, Y, Khaksarian, M, Khalilov, R, Khan, E, Khayamzadeh, M, Khazaee-Pool, M, Khazaei, S, Khosravi Shadmani, F, Khubchandani, J, Kim, D, Kisa, A, Kisa, S, Kocarnik, J, Komaki, H, Kopec, J, Koyanagi, A, Kuipers, E, Kumar, V, La Vecchia, C, Lami, F, Lopez, A, Lopukhov, P, Lunevicius, R, Majeed, A, Majidinia, M, Manafi, A, Manafi, N, Manda, A, Mansour-Ghanaei, F, Mantovani, L, Mehta, D, Meier, T, Meles, H, Mendoza, W, Mestrovic, T, Miazgowski, B, Miazgowski, T, Mir, S, Mirzaei, H, Mohammad, K, Mohammad Gholi Mezerji, N, Mohammadian-Hafshejani, A, Mohammadoo-Khorasani, M, Mohammed, S, Mohebi, F, Mokdad, A, Monasta, L, Moossavi, M, Moradi, G, Moradpour, F, Moradzadeh, R, Nahvijou, A, Naik, G, Najafi, F, Nazari, J, Negoi, I, Negru, S, Nguyen, C, Nguyen, T, Ningrum, D, Ogbo, F, Olagunju, A, Olagunju, T, Pana, A, Pereira, D, Pirestani, M, Pourshams, A, Poustchi, H, Qorbani, M, Rabiee, M, Rabiee, N, Radfar, A, Rahmati, M, Rajati, F, Raoofi, S, Rawaf, D, Rawaf, S, Reiner, R, Renzaho, A, Rezaei, N, Rezapour, A, Saad, A, Saadatagah, S, Saddik, B, Salehi, F, Zahabi, S, Salz, I, Samy, A, Sanabria, J, Santric Milicevic, M, Sarveazad, A, Satpathy, M, Schneider, I, Sekerija, M, Shaahmadi, F, Shabaninejad, H, Shamsizadeh, M, Sharafi, Z, Sharif, M, Sharifi, A, Sheikhbahaei, S, Shirkoohi, R, Siddappa Malleshappa, S, Silva, D, Sisay, M, Smarandache, C, Soofi, M, Soreide, K, Soshnikov, S, Starodubov, V, Tabares-Seisdedos, R, Sullman, M, Taherkhani, A, Tesfay, B, Topor-Madry, R, Traini, E, Tran, B, Tran, K, Ullah, I, Uthman, O, Vacante, M, Vahedian-Azimi, A, Valli, A, Varavikova, E, Vujcic, I, Westerman, R, Yazdi-Feyzabadi, V, Yisma, E, Yu, C, Zadnik, V, Zahirian Moghadam, T, Zaki, L, Zandian, H, Zhang, Z, Murray, C, Naghavi, M, Malekzadeh, R, Safiri S., Sepanlou S. G., Ikuta K. S., Bisignano C., Salimzadeh H., Delavari A., Ansari R., Roshandel G., Merat S., Fitzmaurice C., Force L. M., Nixon M. R., Abbastabar H., Abegaz K. H., Afarideh M., Ahmadi A., Ahmed M. B., Akinyemiju T., Alahdab F., Ali R., Alikhani M., Alipour V., Aljunid S. M., Almadi M. A. H., Almasi-Hashiani A., Al-Raddadi R. M., Alvis-Guzman N., Amini S., Anber N. H., Ansari-Moghaddam A., Arabloo J., Arefi Z., Asghari Jafarabadi M., Azadmehr A., Badawi A., Baheiraei N., Barnighausen T. W., Basaleem H., Behzadifar M., Belayneh Y. M., Berhe K., Bhattacharyya K., Biadgo B., Bijani A., Biondi A., Bjorge T., Borzi A. M., Bosetti C., Bou-Orm I. R., Brenner H., Briko A. N., Briko N. I., Carreras G., Carvalho F., Castaneda-Orjuela C. A., Cerin E., Chiang P. P. -C., Chido-Amajuoyi O. G., Daryani A., Davitoiu D. V., Demoz G. T., Desai R., Dianati Nasab M., Eftekhari A., El Sayed I., Elbarazi I., Emamian M. H., Endries A. Y., Esmaeilzadeh F., Esteghamati A., Etemadi A., Farzadfar F., Fernandes E., Fernandes J. C., Filip I., Fischer F., Foroutan M., Gad M. M., Gallus S., Ghaseni-Kebria F., Ghashghaee A., Gorini G., Hafezi-Nejad N., Haj-Mirzaian A., Hasanpour-Heidari S., Hasanzadeh A., Hassanipour S., Hay S. I., Hoang C. L., Hostiuc M., Househ M., Ilesanmi O. S., Ilic M. D., Innos K., Irvani S. S. N., Islami F., Jaca A., Jafari Balalami N., Jafari Delouei N., Jafarinia M., Jahani M. A., Jakovljevic M., James S. L., Javanbakht M., Jenabi E., Jha R. P., Joukar F., Kasaeian A., Kassa T. D., Kassaw M. W., Kengne A. P., Khader Y. S., Khaksarian M., Khalilov R., Khan E. A., Khayamzadeh M., Khazaee-Pool M., Khazaei S., Khosravi Shadmani F., Khubchandani J., Kim D., Kisa A., Kisa S., Kocarnik J. M., Komaki H., Kopec J. A., Koyanagi A., Kuipers E. J., Kumar V., La Vecchia C., Lami F. H., Lopez A. D., Lopukhov P. D., Lunevicius R., Majeed A., Majidinia M., Manafi A., Manafi N., Manda A. -L., Mansour-Ghanaei F., Mantovani L. G., Mehta D., Meier T., Meles H. G., Mendoza W., Mestrovic T., Miazgowski B., Miazgowski T., Mir S. M., Mirzaei H., Mohammad K. A., Mohammad Gholi Mezerji N., Mohammadian-Hafshejani A., Mohammadoo-Khorasani M., Mohammed S., Mohebi F., Mokdad A. H., Monasta L., Moossavi M., Moradi G., Moradpour F., Moradzadeh R., Nahvijou A., Naik G., Najafi F., Nazari J., Negoi I., Negru S., Nguyen C. T., Nguyen T. H., Ningrum D. N. A., Ogbo F. A., Olagunju A. T., Olagunju T. O., Pana A., Pereira D. M., Pirestani M., Pourshams A., Poustchi H., Qorbani M., Rabiee M., Rabiee N., Radfar A., Rahmati M., Rajati F., Raoofi S., Rawaf D. L., Rawaf S., Reiner R. C., Renzaho A. M. N., Rezaei N., Rezapour A., Saad A. M., Saadatagah S., Saddik B., Salehi F., Zahabi S. S., Salz I., Samy A. M., Sanabria J., Santric Milicevic M. M., Sarveazad A., Satpathy M., Schneider I. J. C., Sekerija M., Shaahmadi F., Shabaninejad H., Shamsizadeh M., Sharafi Z., Sharif M., Sharifi A., Sheikhbahaei S., Shirkoohi R., Siddappa Malleshappa S. K., Silva D. A. S., Sisay M., Smarandache C. -G., Soofi M., Soreide K., Soshnikov S., Starodubov V. I., Tabares-Seisdedos R., Sullman M., Taherkhani A., Tesfay B. E., Topor-Madry R., Traini E., Tran B. X., Tran K. B., Ullah I., Uthman O. A., Vacante M., Vahedian-Azimi A., Valli A., Varavikova E., Vujcic I. S., Westerman R., Yazdi-Feyzabadi V., Yisma E., Yu C., Zadnik V., Zahirian Moghadam T., Zaki L., Zandian H., Zhang Z. -J., Murray C. J. L., Naghavi M., and Malekzadeh R.

Abstract

Background: Data about the global, regional, and country-specific variations in the levels and trends of colorectal cancer are required to understand the impact of this disease and the trends in its burden to help policy makers allocate resources. Here we provide a status report on the incidence, mortality, and disability caused by colorectal cancer in 195 countries and territories between 1990 and 2017. Methods: Vital registration, sample vital registration, verbal autopsy, and cancer registry data were used to generate incidence, death, and disability-adjusted life-year (DALY) estimates of colorectal cancer at the global, regional, and national levels. We also determined the association between development levels and colorectal cancer age-standardised DALY rates, and calculated DALYs attributable to risk factors that had evidence of causation with colorectal cancer. All of the estimates are reported as counts and age-standardised rates per 100 000 person-years, with some estimates also presented by sex and 5-year age groups. Findings: In 2017, there were 1·8 million (95% UI 1·8–1·9) incident cases of colorectal cancer globally, with an age-standardised incidence rate of 23·2 (22·7–23·7) per 100 000 person-years that increased by 9·5% (4·5–13·5) between 1990 and 2017. Globally, colorectal cancer accounted for 896 000 (876 300–915 700) deaths in 2017, with an age-standardised death rate of 11·5 (11·3–11·8) per 100 000 person-years, which decreased between 1990 and 2017 (−13·5% [–18·4 to −10·0]). Colorectal cancer was also responsible for 19·0 million (18·5–19·5) DALYs globally in 2017, with an age-standardised rate of 235·7 (229·7–242·0) DALYs per 100 000 person-years, which decreased between 1990 and 2017 (−14·5% [–20·4 to −10·3]). Slovakia, the Netherlands, and New Zealand had the highest age-standardised incidence rates in 2017. Greenland, Hungary, and Slovakia had the highest age-standardised death rates in 2017. Numbers of incident cases and deaths were higher

Published
2019

25. Colon capsule endoscopy in colorectal cancer screening: A systematic review

Author

Vuik, F. E. R., Nieuwenburg, S. A. V., Moen, S., Spada, Cristiano, Senore, C., Hassan, Cesare, Pennazio, M., Rondonotti, E., Pecere, Silvia, Kuipers, E. J., Spaander, M. C. W., Spada C. (ORCID:0000-0002-5692-0960), Hassan C., Pecere S., Vuik, F. E. R., Nieuwenburg, S. A. V., Moen, S., Spada, Cristiano, Senore, C., Hassan, Cesare, Pennazio, M., Rondonotti, E., Pecere, Silvia, Kuipers, E. J., Spaander, M. C. W., Spada C. (ORCID:0000-0002-5692-0960), Hassan C., and Pecere S.

Abstract

Introduction Primary colonoscopy and fecal immunochemical test (FIT) are the most commonly used colorectal cancer (CRC) screening modalities. Colon capsule endoscopy (CCE) might be an alternative. Data on the performance of CCE as a CRC screening tool in a screening population remain scarce. This is the first systematic review to provide an overview of the applicability of CCE as a CRC screening tool. Methods A systematic search was conducted of literature published up to September 2020. Studies reporting on CRC screening by second-generation CCE in an average-risk screening population were included. Results 582 studies were identified and 13 were included, comprising 2485 patients. Eight studies used CCE as a filter test after a positive FIT result and five studies used CCE for primary screening. The polyp detection rate of CCE was 24 % - 74 %. For polyps > 6 mm, sensitivity of CCE was 79 % - 96 % and specificity was 66 % - 97 %. For polyps ≥ 10 mm, sensitivity of CCE was 84 % - 97 %, which was superior to computed tomographic colonography (CTC). The CRC detection rate for completed CCEs was 93 % (25/27). Bowel preparation was adequate in 70 % - 92 % of examinations, and completion rates varied from 57 % to 92 %, depending on the booster used. No CCE-related complications were described. Conclusion CCE appeared to be a safe and effective tool for the detection of CRC and polyps in a screening setting. Accuracy was comparable to colonoscopy and superior to CTC, making CCE a good alternative to colonoscopy in CRC screening programs, although completion rates require improvement.

Published
2021

48. Pharmaceutical care in obstructive lung diseases: current and future practice

Author

Kuipers, E., Smet, P.A.G.M. de, Wensing, M.J.P., Teichert, M., and Radboud University Nijmegen

Subjects
Radboud Institute for Health Sciences, Healthcare improvement science [Radboudumc 18], Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]
Abstract

Contains fulltext : 216173.pdf (Publisher’s version ) (Open Access) Radboud University, 20 februari 2020 Promotores : Smet, P.A.G.M. de, Wensing, M.J.P. Co-promotor : Teichert, M.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results